Citation

Lindenberg F, Sichel F, Lechevrel M, Respaud R, Saint-Lorant G (2019) Evaluation of Lung Cell Toxicity of Surfactants for Inhalation Route. J Toxicol Risk Assess 5:022. doi.org/10.23937/2572-4061.1510022

Copyright

© 2019 Lindenberg F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

SHORT COMMUNICATION | OPEN ACCESS DOI: 10.23937/2572-4061.1510022

Evaluation of Lung Cell Toxicity of Surfactants for Inhalation Route

Lindenberg F1,2*, Sichel F1,3, Lechevrel M1 , Respaud R4 and Saint-Lorant G1,2

1Normandie Univ, UNICAEN, ABTE, Caen 14000, France

2Department of Pharmacy, CHU de Caen, Caen 14000, France

3Centre François Baclesse, Caen 14000, France

4Service de Pharmacie, Centre d'Etude des Pathologies Respiratoires, Université François-Rabelais de Tours, France

Abstract

Few data are available for excipients administered by inhalation route. This study evaluated the in vitro potential toxicity of three surfactants (Polysorbate 20, Polysorbate 80 and Poloxamer 188) by using an original air-liquid interface (ALI) method of exposure compared to liquid/liquid (L/L) model. Two cell toxicity tests were conducted on BEAS-2B cells, a human immortalized bronchial epithelial cell lines; measurement of Lactate Dehydrogenase activity and XTT cell proliferation assay. We found that Polysorbate 20 appeared to be more toxic than Polysorbate 80, Poloxamer 188. An increased toxicity of Polysorbate 20 in L/L system as shown in comparison to ALI exposure. A toxicity was also observed for polysorbate 80 but at higher concentrations and without difference between L/L and ALI exposure. No toxicity was observed for Poloxamer 188 at high concentrations.

Poloxamer 188 seems to be the better candidate, out of the three tested, for galenic formulations designed to the inhalation route such as biotherapies. To evaluate the cytotoxicity of excipients for inhalation route the ALI exposure have to be used instead of L/L.